

Xue-Hai Liang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2075991/publications.pdf>

Version: 2024-02-01

57
papers

3,983
citations

109311

35
h-index

144002

57
g-index

57
all docs

57
docs citations

57
times ranked

3207
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular uptake and trafficking of antisense oligonucleotides. <i>Nature Biotechnology</i> , 2017, 35, 230-237.	17.5	416
2	Antisense technology: an overview and prospectus. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 427-453.	46.4	299
3	Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. <i>Nature Biotechnology</i> , 2019, 37, 640-650.	17.5	205
4	rRNA Modifications in an Intersubunit Bridge of the Ribosome Strongly Affect Both Ribosome Biogenesis and Activity. <i>Molecular Cell</i> , 2007, 28, 965-977.	9.7	192
5	Loss of rRNA modifications in the decoding center of the ribosome impairs translation and strongly delays pre-rRNA processing. <i>Rna</i> , 2009, 15, 1716-1728.	3.5	186
6	RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. <i>Molecular Therapy</i> , 2017, 25, 2075-2092.	8.2	168
7	Phosphorothioate modified oligonucleotide-protein interactions. <i>Nucleic Acids Research</i> , 2020, 48, 5235-5253.	14.5	163
8	Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. <i>Nucleic Acids Research</i> , 2015, 43, 2927-2945.	14.5	151
9	Antisense technology: A review. <i>Journal of Biological Chemistry</i> , 2021, 296, 100416.	3.4	149
10	Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. <i>Nature Biotechnology</i> , 2016, 34, 875-880.	17.5	137
11	² -Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54 ^{nrb} and PSF. <i>Nucleic Acids Research</i> , 2015, 43, 4569-4578.	14.5	97
12	Phosphorothioate oligonucleotides can displace NEAT1 RNA and form nuclear paraspeckle-like structures. <i>Nucleic Acids Research</i> , 2014, 42, 8648-8662.	14.5	87
13	Viable RNaseH1 knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function. <i>Nucleic Acids Research</i> , 2016, 44, 5299-5312.	14.5	84
14	Antisense oligonucleotides targeting translation inhibitory elements in 5' UTRs can selectively increase protein levels. <i>Nucleic Acids Research</i> , 2017, 45, 9528-9546.	14.5	83
15	TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells. <i>Nucleic Acids Research</i> , 2014, 42, 7819-7832.	14.5	80
16	Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. <i>Nucleic Acids Research</i> , 2019, 47, 5465-5479.	14.5	77
17	The Interaction of Phosphorothioate-Containing RNA Targeted Drugs with Proteins Is a Critical Determinant of the Therapeutic Effects of These Agents. <i>Journal of the American Chemical Society</i> , 2020, 142, 14754-14771.	13.7	77
18	The Helicase Has1p Is Required for snoRNA Release from Pre-rRNA. <i>Molecular and Cellular Biology</i> , 2006, 26, 7437-7450.	2.3	75

#	ARTICLE	IF	CITATIONS
19	Acute hepatotoxicity of 2'-fluoro-modified 5'-phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. <i>Nucleic Acids Research</i> , 2018, 46, 2204-2217.	14.5	71
20	Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity. <i>Nucleic Acids Research</i> , 2016, 44, 3892-3907.	14.5	65
21	Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. <i>Nucleic Acids Research</i> , 2020, 48, 1691-1700.	14.5	63
22	Efficient and specific knockdown of small non-coding RNAs in mammalian cells and in mice. <i>Nucleic Acids Research</i> , 2011, 39, e13-e13.	14.5	62
23	Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides. <i>Nucleic Acids Research</i> , 2021, 49, 9026-9041.	14.5	61
24	Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides. <i>Nucleic Acids Research</i> , 2017, 45, 5309-5322.	14.5	60
25	Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides. <i>Nucleic Acids Research</i> , 2016, 44, gkw595.	14.5	58
26	Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. <i>Nucleic Acids Research</i> , 2018, 46, 3579-3594.	14.5	58
27	RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery. <i>Nucleic Acids Research</i> , 2016, 44, 3351-3363.	14.5	57
28	Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins. <i>Journal of the American Chemical Society</i> , 2020, 142, 7456-7468.	13.7	56
29	Antisense drug discovery and development technology considered in a pharmacological context. <i>Biochemical Pharmacology</i> , 2021, 189, 114196.	4.4	55
30	Depletion of key protein components of the RISC pathway impairs pre-ribosomal RNA processing. <i>Nucleic Acids Research</i> , 2011, 39, 4875-4889.	14.5	50
31	Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides. <i>Nucleic Acids Research</i> , 2017, 45, 10649-10671.	14.5	50
32	Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells. <i>Nucleic Acid Therapeutics</i> , 2019, 29, 245-255.	3.6	48
33	Dynamic nucleoplasmic and nucleolar localization of mammalian RNase H1 in response to RNAP I transcriptional R-loops. <i>Nucleic Acids Research</i> , 2017, 45, 10672-10692.	14.5	44
34	Human RNase H1 Is Associated with Protein P32 and Is Involved in Mitochondrial Pre-rRNA Processing. <i>PLoS ONE</i> , 2013, 8, e71006.	2.5	43
35	Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2013, 1829, 455-468.	1.9	36
36	mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway. <i>Nucleic Acids Research</i> , 2019, 47, 6900-6916.	14.5	32

#	ARTICLE	IF	CITATIONS
37	Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes. <i>Nucleic Acids Research</i> , 2020, 48, 1372-1391.	14.5	32
38	COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways. <i>Nucleic Acids Research</i> , 2018, 46, 10225-10245.	14.5	31
39	Site-specific incorporation of 5â€²-methyl DNA enhances the therapeutic profile of gapmer ASOs. <i>Nucleic Acids Research</i> , 2021, 49, 1828-1839.	14.5	26
40	Depletion of NEAT1 lncRNA attenuates nucleolar stress by releasing sequestered P54nrb and PSF to facilitate c-Myc translation. <i>PLoS ONE</i> , 2017, 12, e0173494.	2.5	26
41	Strong dependence between functional domains in a dual-function snoRNA infers coupling of rRNA processing and modification events. <i>Nucleic Acids Research</i> , 2010, 38, 3376-3387.	14.5	17
42	Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs. <i>Nucleic Acids Research</i> , 2018, 46, 293-313.	14.5	15
43	Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 686-698.	5.1	15
44	Specific Increase of Protein Levels by Enhancing Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames. <i>Advances in Experimental Medicine and Biology</i> , 2017, 983, 129-146.	1.6	15
45	Some ASOs that bind in the coding region of mRNAs and induce RNase H1 cleavage can cause increases in the pre-mRNAs that may blunt total activity. <i>Nucleic Acids Research</i> , 2020, 48, 9840-9858.	14.5	14
46	Site-specific Incorporation of 2â€²,5â€²-Linked Nucleic Acids Enhances Therapeutic Profile of Antisense Oligonucleotides. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 922-927.	2.8	13
47	RNA helicase A is not required for RISC activity. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2013, 1829, 1092-1101.	1.9	10
48	Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins. <i>Nucleic Acids Research</i> , 2021, 49, 2721-2739.	14.5	10
49	Solid-Phase Separation of Toxic Phosphorothioate Antisense Oligonucleotide-Protein Nucleolar Aggregates Is Cytoprotective. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 126-144.	3.6	10
50	Structural basis of dimerization and nucleic acid binding of human DBHS proteins NONO and PSPC1. <i>Nucleic Acids Research</i> , 2022, 50, 522-535.	14.5	10
51	Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly. <i>Nucleic Acid Therapeutics</i> , 2019, 29, 343-358.	3.6	9
52	Gapmer Antisense Oligonucleotides Targeting 5S Ribosomal RNA Can Reduce Mature 5S Ribosomal RNA by Two Mechanisms. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 312-324.	3.6	7
53	Golgi-58K can re-localize to late endosomes upon cellular uptake of PS-ASOs and facilitates endosomal release of ASOs. <i>Nucleic Acids Research</i> , 2021, 49, 8277-8293.	14.5	7
54	RNA modifications can affect RNase H1-mediated PS-ASO activity. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 814-828.	5.1	7

#	ARTICLE	IF	CITATIONS
55	Insights into innate immune activation via PS-ASO-protein-TLR9 interactions. <i>Nucleic Acids Research</i> , 2022, 50, 8107-8126.	14.5	7
56	Hsc70 Facilitates Mannose-6-Phosphate Receptor-Mediated Intracellular Trafficking and Enhances Endosomal Release of Phosphorothioate-Modified Antisense Oligonucleotides. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 284-297.	3.6	4
57	Perinuclear positioning of endosomes can affect PS-ASO activities. <i>Nucleic Acids Research</i> , 2021, 49, 12970-12985.	14.5	3